Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 3Genitourinary 3Gastrointestinal 3Dermatologic 3Thoracic 2Gynecologic 2Lymphoid 1Breast 1

Conditions

Ovarian Neoplasms 37Carcinoma, Non-Small-Cell Lung 23Uterine Cervical Neoplasms 22Melanoma 22Carcinoma, Renal Cell 18Endometrial Neoplasms 16Colorectal Neoplasms 15Carcinoma, Transitional Cell 15Triple Negative Breast Neoplasms 13Stomach Neoplasms 13Fallopian Tube Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Pancreatic Neoplasms 9Breast Neoplasms 9Head and Neck Neoplasms 8Carcinoma, Ovarian Epithelial 8Carcinoma, Merkel Cell 8Small Cell Lung Carcinoma 7Prostatic Neoplasms 7Neoplasms 7Neoplasm Metastasis 7Lung Neoplasms 6Esophageal Neoplasms 6Cholangiocarcinoma 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma 4Carcinosarcoma 4Vulvar Neoplasms 3

Interventions

pembrolizumab 4atezolizumab 2Nivolumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Microsatellite Instability × Nivolumab × Gynecologic × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡